Oncolytic Virotherapy in Glioma Tumors

Area of Science:

• Oncology
• Immunotherapy
• Virology

Background:

• Glioma, particularly glioblastoma, presents a significant therapeutic challenge with limited effective treatments.
• Oncolytic immunotherapy, utilizing oncolytic viruses (OVs), has emerged as a promising alternative.
• OVs possess a dual mechanism of action: direct tumor cell lysis and induction of anti-tumor immune responses.

Purpose of the Study:

• To review existing literature on oncolytic viruses (OVs) as a therapeutic strategy for glioma.
• To describe OVs proposed for glioma treatment, categorizing them by viral genome (DNA and RNA).
• To highlight clinical trial outcomes evaluating OVs for glioma.

Main Methods:

• Literature review of oncolytic viruses for glioma treatment.
• Categorization of OVs based on their genomic material (DNA vs. RNA).
• Analysis of in vitro and in vivo study results, including clinical trial data.

Main Results:

• Oncolytic viruses demonstrate direct glioma cell destruction and stimulate tumor-specific immune responses.
• Clinical trials indicate the feasibility of OV therapy with tumor-specific targeting and manageable toxicity.
• Both DNA and RNA viruses are being explored as potential oncolytic agents for glioma.

Conclusions:

• Oncolytic viruses represent a viable and promising therapeutic avenue for glioma treatment.
• OV therapy offers a potential alternative for patients with limited options from conventional treatments.
• Further clinical investigation is warranted to fully establish the role of OVs in glioma management.